Breakthroughs in lung transplantation & advanced therapies are improving survival rates and expanding eligibility criteria for patients with end-stage lung disease. Innovations in ex vivo lung perfusion, donor lung bioengineering, and tolerance-inducing immunomodulation are helping address the persistent challenge of organ shortages and rejection. Multidisciplinary care models now coordinate pre-transplant optimization and post-transplant surveillance using non-invasive biomarkers and imaging. Lung Transplantation & Advanced Therapies also includes regenerative strategies like stem cell therapy, decellularized scaffolds, and gene editing technologies, offering hope for patients previously considered ineligible for transplantation. The ethical, economic, and logistical implications of these therapies are actively under debate, demanding robust policy and clinical frameworks. Global registries, transplant networks, and cross-border collaborations are essential to improve access and outcomes as science reshapes what is surgically and biologically possible.
Title : Global warming and increasing respiratory illnesses
Yazdan Mirzanejad, University of British Columbia, Canada
Title :
Saurabh Chattopadhyay, University of Kentucky, United States
Title : Risk factors for mycobacterium avium complex infections in patients with chronic obstructive pulmonary disease
Alizaman Sadigov, Medical University, United States
Title : Managing integration and interoperability in transformed pulmonology, respiratory medicine and lung health ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Oncology (PPO) to be set up via precision oncology strategy for cancer care team: Developing targeted lung cancer therapy and advancing personalized cancer care
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Advancements in pulmonology and respiratory care through the view of Personalized and Precision Medicine (PPM) and biodesign-driven translational applications
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation